Details:
Under the terms of the agreement, Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal spray) in China (including Chinese mainland, Hong Kong and Macao SAR, Taiwan region).
Lead Product(s): Budesonide
Therapeutic Area: Immunology Product Name: Budesolv
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Luoxin Pharmaceutical
Deal Size: $22.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement October 19, 2021